Birch Pollen Allergy - Pipeline Insight, 2024

This “Birch Pollen Allergy - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Birch Pollen Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Birch Pollen Allergy Understanding

Birch Pollen Allergy: Overview

Birch and other related trees of the families Betulaceae and Fagaceae (alder, hazel, oak, hornbeam, chestnut, and beech) constitute the birch homologous group. This grouping is primarily based on the extensive IgE cross-reactivity of allergen homologs to the major birch allergen Bet v 1. Birch pollen is the most dominant tree pollen in Northern and Central Europe and is a major cause of allergic rhinitis and, possibly, asthma symptoms. Over the last few decades, levels of birch pollen have risen and the period of exposure has increased due to climate changes. Subsequently, the prevalence of birch pollen sensitization has also increased. The cross-reactivity and sequential pollen seasons within the birch homologous group create a prolonged symptomatic allergy period beyond birch pollen alone. Furthermore, many plant food allergens contain homologs to Bet v 1, meaning that the majority of patients with birch pollen allergy suffer from secondary pollen food syndrome (PFS).

Birch Pollen Allergy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Birch Pollen Allergy pipeline landscape is provided which includes the disease overview and Birch Pollen Allergy treatment guidelines. The assessment part of the report embraces, in depth Birch Pollen Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Birch Pollen Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Birch Pollen Allergy.
• In the coming years, the Birch Pollen Allergy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Birch Pollen Allergy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Birch Pollen Allergy treatment market. Several potential therapies for Birch Pollen Allergy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Birch Pollen Allergy market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Birch Pollen Allergy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Birch Pollen Allergy Emerging Drugs Chapters

This segment of the Birch Pollen Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Birch Pollen Allergy Emerging Drugs

DM-101: Desentum Oy DM-101 is a modified birch pollen allergen designed for improving the immunotherapeutic treatment of birch pollen allergy. The company completed a First-in-Human clinical study with the lead product candidate, birch pollen hypoallergen DM-101. Currently, it is in Phase I stage of clinical trial evaluation to treat birch pollenallergy.

Birch Pollen Allergy: Therapeutic Assessment

This segment of the report provides insights about the different Birch Pollen Allergy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Birch Pollen Allergy

There are approx. 5+ key companies which are developing the therapies for Birch Pollen Allergy. The companies which have their Birch Pollen Allergy drug candidates in the most advanced stage, i.e. phase I include, Desentum Oy.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Birch Pollen Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Birch Pollen Allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Birch Pollen Allergy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Birch Pollen Allergy drugs.

Birch Pollen Allergy Report Insights

• Birch Pollen Allergy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Birch Pollen Allergy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Birch Pollen Allergy drugs?
• How many Birch Pollen Allergy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Birch Pollen Allergy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Birch Pollen Allergy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Birch Pollen Allergy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Desentum Oy
• ROXALL Medizin GmbH
• Tolerogenics S.à.r.l.
• Worg Pharmaceuticals

Key Products

• DM-101
• SULGEN Spray Birke (BIA 14-2964)

Research programme: allergy immunotherapies- WP1074


This product will be delivered within 1-3 business days.